Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.

Niezgoda, Adam; Bieganski, Grzegorz; Wachowiak, Jacek; Czarnota, Jaroslaw; Siemionow, Krzysztof; Heydemann, Ahlke; Ziemiecka, Anna; Sikorska, Maria H; Bozyk, Katarzyna; Siemionow, Maria

Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.

Niezgoda, Adam; Bieganski, Grzegorz; Wachowiak, Jacek; Czarnota, Jaroslaw; Siemionow, Krzysztof; Heydemann, Ahlke; Ziemiecka, Anna; Sikorska, Maria H; Bozyk, Katarzyna; Siemionow, Maria.

Afiliação

Niezgoda A; Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.
Bieganski G; Department of Infectious Diseases and Child Neurology, Poznan University of Medical Sciences, Poznan, Poland.
Wachowiak J; Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, Poznan, Poland.
Czarnota J; Hospital MedPolonia, Poznan, Poland.
Siemionow K; Dystrogen Therapeutics Corp., Chicago, IL, USA.
Heydemann A; Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL, USA.
Ziemiecka A; Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, IL, USA.
Sikorska MH; Center for Cardiovascular Research, University of Illinois at Chicago, Chicago, IL, USA.
Bozyk K; Dystrogen Therapeutics Corp., Chicago, IL, USA.
Siemionow M; Dystrogen Therapeutics Corp., Chicago, IL, USA.

Arch Immunol Ther Exp (Warsz) ; 71(1): 24, 2023 Nov 24.

Article em En | MEDLINE | ID: mdl-37999748

Assuntos

Distrofia Muscular de Duchenne; Masculino; Humanos; Criança; Adolescente; Distrofia Muscular de Duchenne/tratamento farmacológico; Distrofia Muscular de Duchenne/genética; Distrofina/genética; Músculo Esquelético; Biomarcadores; Terapia Baseada em Transplante de Células e Tecidos

Palavras-chave

Biomarker; Duchenne muscular dystrophy; Dystrophin Expressing Chimeric (DEC) cell; Electromyography (EMG); Safety; Stem cell therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Temas: ECOS / Aspectos_gerais Bases de dados: MEDLINE Assunto principal: Distrofia Muscular de Duchenne Limite: Adolescent / Child / Humans / Male Idioma: En Revista: Arch Immunol Ther Exp (Warsz) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Polônia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google